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274* RhDNase before or after going to sleep in children with cystic
ﬁbrosis?
L.J. van der Giessen1, R. Gosselink2, W. Hop3, H. Tiddens4. 1Department of
Paediatric Physiotherapy, Erasmus MC – Sophia Children’s Hospital, Rotterdam,
Netherlands; 2Department of Respiratory Rehabilitation, University Hospital,
Leuven, Belgium; 3Department of Epidemiology & Biostatistics, Erasmus MC,
Rotterdam, Netherlands; 4Department of Paediatrics, Respiratory Medicine and
Allergology, Erasmus MC – Sophia children’s Hospital, Rotterdam, Netherlands
Objective: To compare in patients with CF who are on maintenance therapy with
rhDNase the efﬁcacy and possible side effects of nebulisation of rhDNase before
sleep to nebulisation in the morning.
Methods: Design: randomized, double blind, double dummy, cross over study.
Inclusion criteria: CF, stable clinical condition, rhDNase maintenance therapy.
Children in Group I inhaled rhDNase before sleep, and a placebo in the morning
in week 1−2. The protocol was reversed during week 3−4. Group II performed
the reversed sequence. Patients continued their daily routine sputum expectoration.
Primary endpoint: MEF25. Pulmonary functions tests were performed on day 0, 7,
14, 21 and 28. After 1, 2, 3 and 4 weeks oxygen saturation and cough frequency
were measured during the night.
Results: 24 patients completed the study. Mean age: 13 years (range 6−19). MEF25
(%pred) as primary endpoint did not show a signiﬁcant difference between nebu-
lisation of rhDNase before sleep versus nebulisation of rhDNase in the morning.
Nocturnal cough, oxygen saturation, or any of the other secondary end points were
not signiﬁcantly different between the two study periods.
Conclusion: This study showed in children with CF lung disease who are on
maintenance treatment with rhDNase that it is equally effective and safe to nebulise
rhDNase before going to sleep compared to nebulisation in the morning.
275 Questionnaire survey of stress urinary incontinence (UI) in
9−16 year olds with cystic ﬁbrosis, compared to other chronic
respiratory conditions and a normal group
W.J. Browne1, C.J. Wood1, M. Desai2, P.H. Weller2. 1Physiotherapy, Birmingham
Children’s Hospital, United Kingdom; 2Respiratory Medicine, Birmingham Children’s
Hospital, United Kingdom
Aims: To report incidence, degree and impact of UI in 9−16 year olds with CF,
compared to controls and clinical status.
Method: Children aged 9−16 years, from clinics at a tertiary centre. Group 1: CF
clinic. Group 2: Respiratory clinic (chronic cough-asthma, bronchiectasis or PCD);
main cause of UI in CF is cough [1]. Group 3: Normal control (fracture clinic). At
clinic – consented before self administered questionnaire (Group 3: short anonymous
version). Data collected: sex, age, % predicted FVC & FEV1, height, weight and BMI
z scores. Group 3: age & sex only.
Results: Little difference in baseline data, except Group 1 were shorter (p = 0.071).
No statistically signiﬁcant difference between incidence of wetting, on more than
1 occasion. Laughing, exercise & cough were the most common causes of UI. No
difference between wetters for age range, lung function, physiotherapy, breathlessness,
antibiotics, urinary tract infections, menarche. Only 3 (group 1) and 2 (group 2) report
more than a few drops of UI.
Conclusion: No difference was shown in incidence of UI between the groups. Reported
incidence is similar to that of other studies without control groups in CF children, but
also in healthy adolescents [2].
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Group 1: CF (N= 81) Group 2: Respiratory (N= 55) Group 3: Normal (N = 58)
Girls Boys Girls Boys Girls Boys (2 unknown)
Numbers 36 45 21 34 28 28
Age (Range) 12.1 (9.2−16.9) 12.6 (9.0−16.7) 12.3 (9.6−16.2) 12.9 (9.0−16.9) 11.3 (9.2−16.1) 12.88 (9.6−16.0)
Wetting on more 11 (30%) 6 (13%) 4 (19%) 8 (31%) 7 (25%) 3 (11%)
than 1 occasion 17 (21%) 12 (22%) 10 (17%)
276 Perception versus objective assessment of diseases severity in
cohort adult cystic ﬁbrosis (CF) patients
H. Douglass, C. Hayward, J. Dyer, C. Ryder, J. Bond-Kendall, N.A. Jarad. Adult
CF Centre, Bristol Royal Inﬁrmary, Bristol, BS2 8HW, United Kingdom
Introduction: The aims of this research is to investigate whether the degree of dis-
ease severity as assessed by adult CF patients (perception) correalte with recognised
CF outcome measures. This was compared with an objective performance score.
Patients and methods: We investigated 76 adult CF patients (29 female), mean
age 26.6, range 17−42 years. At their 2006 annual assessment, perception of health
score (PHS) was estimated by patients’ scoring their own health status. This was
graded on a scale 0−10. Objective performance score (OPS) was estimated by
summation of 4 domains (score 1−5 in each). These were: breathlessness score,
chest examination score, chest radiograph score and BMI score. This systme was
validated: (Middleditch AG, Jarad NA. Am J Respir Crit Care Med 2003;167:A499).
Factors assessed for comparison were: age, sex, FEV1, annual number of pulmonary
severe exacerbations (P Exs) and treatment burden.
Results: Out of 76 patients 64 (84%) OPS and 56 (74%) PHS was available for
comparison. There was no difference between female and male patients with regards
to either score and neither scoring system correlated with age. OPS correlated with
PHS, r = 0.63, P< 0.0001. Both scores correlated with percentage predicted FEV1
although OPS correlated more closely than PHS, r = 0.79, P< 0.0001 for OPS and
r = 0.53, P< 0.0001 for PHS. Both scores inversely correlated with the number of
P Exs (r = −0.33, P = 0.013 for PHS) and (r = −0.54, P< 0.001 for OPS), and with
the treatment burden.
Conclusion:We found that both, own health score and objective performance score
correlated with known outcome measures in patients with cystic ﬁbrosis. There was
a closer correlation for performance score.
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Musculoskeletal pain is prevalent in cystic ﬁbrosis (CF). The aim of this study was
to examine the effect of musculoskeletal physiotherapy techniques and soft tissue
therapy, including massage on pain and ease of breathing (EOB) in adults with CF.
Methods: 129 adults with CF (60 males, 70 with acute exacerbation), including 24
post lung transplant with a mean (±SD) age of 31±9 years and FEV1% predicted
of 51±21 participated in this study. Following assessment of pain regions, each
subject underwent a single individualized session including spinal joint/intercostal
mobilisation, soft tissue therapy, exercises and postural advice of one hour duration.
Subjects rated their pain levels and EOB on a visual analogue scale (VAS) prior to
and at the session’s conclusion.
Results: Pain was most commonly reported in the thoracic spine region (38%
of subjects), followed by the shoulder region (31%), cervical spine region (16%),
chest wall region (9%) and lumbar spine region (9%). EOB rating prior to treatment
were worst in those with low BMI (r = −0.21, p = 0.02) and low FEV1% predicted
(r = −0.24, p = 0.01). A single treatment session was associated with reduction in
pain (p< 0.05) and improvement in EOB (p< 0.05), irrespective of clinical or
transplant status. Improvement in pain was equivalent for all primary pain regions.
However, greater improvement in EOB was evident in subjects with shoulder pain
compared to other regions (p< 0.05).
Conclusions: A combination of musculoskeletal physiotherapy techniques, exercise
prescription and soft tissue therapy reduces musculoskeletal pain and improves EOB
in adults with stable CF, during an acute exacerbation and post lung transplantation.
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